Novavax: There is 'insufficient evidence' tying its COVID-19 vaccine to heart inflammation
marketwatch.com
news
2022-06-03 17:34:56

Novavax Inc. NVAX, -22.24% said Friday that the company believes "there is insufficient evidence to establish a causal relationship" between its COVID-19 vaccine candidate and instances of myocarditis and pericarditis. Novavax's stock tumbled about 22% in trading on Friday after the Food and Drug Administration said the company's experimental two-dose vaccine could have a higher risk for myocarditis than what has been reported for the mRNA vaccines since they were authorized. (Both the Moderna Inc.
